000049242 000__ 01494cam\a22003615i\4500
000049242 001__ 49242
000049242 003__ SzGeWIPO
000049242 005__ 20240322214828.0
000049242 006__ m    eo  d        
000049242 007__ cr bn |||m|||a
000049242 008__ 240321s2010\\\\enk\\\\\\\\\\u000\0\eng\d
000049242 022__ $$a2044-7175
000049242 035__ $$a(OCoLC)1427545460
000049242 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000049242 041__ $$aeng
000049242 043__ $$ae-uk---
000049242 084__ $$aGB 139
000049242 24500 $$aNot all IP law is transferable.
000049242 264_1 $$aLondon, England:$$bInforma, U.K.$$c2010.
000049242 300__ $$aGB 139 June 2010 ;$$c[28] cm
000049242 336__ $$atext$$2rdacontent
000049242 337__ $$acomputer$$2rdamedia
000049242 338__ $$aonline resource$$bcr$$2rdacarrier
000049242 520__ $$aFaraz Kermani, Scrip Analyst, says that the pharma sector is a case in point The battle for supremacy between Europe and the US in the fields of pharmaceutical R&D and innovation has pointlessly flared up once again. A recently published survey by international intellectual property specialists Marks & Clerk indicates that the US IP system is viewed as being more favourable to innovation and that President Obama's recently passed healthcare reforms are proving to be increasingly palatable for big pharma.
000049242 650_0 $$aIntellectual property.
000049242 650_0 $$aPharmaceuticals.
000049242 650_0 $$aTechnological innovation.
000049242 650_0 $$aPatents.
000049242 7001_ $$aKermani, Faraz,$$eauthor.
000049242 903__ $$aIntellectual Property Magazine
000049242 942__ $$cART$$jGB 139 June 2010$$2ddc
000049242 980__ $$aBIB
000049242 999__ $$c28508$$d28508